Wellness

Quick links
Turn on suggestions Auto-suggest helps you quickly narrow down your search results by suggesting possible matches as you type.
Auto-suggest helps you quickly narrow down your search results by suggesting possible matches as you type.
Showing results for 
Search instead for 
Do you mean 
Reply
Esteemed Contributor
Mary Bailey
Posts: 6,375
Registered: ‎03-09-2010

FDA Alert email: Osteoporosis Drugs!

‎07-21-2011 09:41 PM

I quit taking Actonel last month because I spoke to a 84yo woman that thought it caused her bone loss and she spent $50,000 in dental implants.
.
.
.
today I get this FDA Alert Email:
.
.
.
.
Sent to subscribers of: alendronate systemic, etidronate systemic, ibandronate systemic, risedronate systemic, tiludronate systemic, alendronate, etidronate, ibandronate, risedronate, bisphosphonates
July 21, 2011
Audience: Geriatrics, Family Practice, Internal Medicine.
Includes: Fosamax (alendronate), Actonel (risedronate), Boniva (ibandronate), Atelvia (risedronate delayed release), Didronel (etidronate), and Skelid (tiludronate)
ISSUE: FDA notified healthcare professionals and patients about its ongoing review of data from published studies to evaluate whether use of oral bisphosphonate drugs is associated with an increased risk of cancer of the esophagus. FDA has not concluded that taking an oral bisphosphonate drug increases the risk of esophageal cancer. There are insufficient data to recommend endoscopic screening of asymptomatic patients. FDA will continue to evaluate all available data supporting the safety and effectiveness of bisphosphonate drugs and will update the public when more information becomes available.
Report Inappropriate Content
Message 1 of 1 (131 Views)
Reply
0 Hearts